Xbrane Biopharma AB (SE:XBRANE)
:XBRANE
XBRANE Stock Chart & Stats
kr10.37
>-kr0.01(-2.10%)
At close: 4:00 PM EST
kr10.37
>-kr0.01(-2.10%)
Day’s Range― - ―
52-Week Rangekr5.42 - kr38.03
Previous CloseN/A
Volume1.93M
Average Volume (3M)117.17K
Market Cap
kr144.03M
Enterprise Valuekr56.82M
Total Cash (Recent Filing)kr86.59M
Total Debt (Recent Filing)kr58.31M
Price to Earnings (P/E)122.0
Beta0.74
Next Earnings
May 05, 2026EPS Estimate
-0.52Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.28
Shares Outstanding20,605,349
10 Day Avg. Volume189,097
30 Day Avg. Volume117,165
Financial Highlights & Ratios
PEG Ratio-1.22
Price to Book (P/B)27.69
Price to Sales (P/S)101.88
P/FCF Ratio-61.92
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-4.14
Revenue Forecast (FY)kr186.50M
Bulls Say, Bears Say
Bulls Say
Stronger 2025 Balance SheetThe marked reduction in debt and large equity increase materially lowers leverage and refinancing pressure, giving management more runway to fund R&D, partnerships and regulatory activities without immediate reliance on dilutive financing. This improves resilience across the next 2–6 months.
Partnership/licensing Revenue ModelA business model focused on out-licensing, upfronts, milestones and royalties provides non-operational, event-driven cash inflows and allows risk transfer to commercialization partners. This structure reduces the need for large commercial capex and supports capital efficiency over a medium-term horizon.
In-house Biologics Development & ManufacturingOwning development and manufacturing capabilities is a durable competitive asset for biosimilars: it supports faster tech transfers, quality control and service offerings to partners, strengthens negotiating position in collaborations and can enable contract revenue or lower development outsourcing costs.
Bears Say
Persistent Negative Cash FlowConsistent and deep negative operating and free cash flow forces continuous external financing or asset sales to sustain operations. Even with a stronger 2025 balance sheet, ongoing cash burn heightens funding and execution risk for trials and manufacturing over the next several months.
Continual Operating LossesPersistent negative operating results indicate the core business has not achieved sustainable profitability, meaning reported net income gains are not from operations. This limits internal funding capacity and increases dependence on partners and capital markets for growth and milestone execution.
Volatile And Declining RevenueMaterial revenue volatility and consecutive declines reduce predictability of milestone and royalty receipts, complicate budgeting for development programs and weaken credibility with partners, raising the probability of additional external funding needs or program delays in the medium term.
Xbrane Biopharma AB News
XBRANE FAQ
What was Xbrane Biopharma AB’s price range in the past 12 months?
Xbrane Biopharma AB lowest stock price was kr5.42 and its highest was kr38.03 in the past 12 months.
What is Xbrane Biopharma AB’s market cap?
Xbrane Biopharma AB’s market cap is kr144.03M.
When is Xbrane Biopharma AB’s upcoming earnings report date?
Xbrane Biopharma AB’s upcoming earnings report date is May 05, 2026 which is in 29 days.
How were Xbrane Biopharma AB’s earnings last quarter?
Xbrane Biopharma AB released its earnings results on Feb 20, 2026. The company reported -kr1.28 earnings per share for the quarter, beating the consensus estimate of -kr1.49 by kr0.21.
Is Xbrane Biopharma AB overvalued?
According to Wall Street analysts Xbrane Biopharma AB’s price is currently Overvalued.
Does Xbrane Biopharma AB pay dividends?
Xbrane Biopharma AB does not currently pay dividends.
What is Xbrane Biopharma AB’s EPS estimate?
Xbrane Biopharma AB’s EPS estimate is -0.52.
How many shares outstanding does Xbrane Biopharma AB have?
Xbrane Biopharma AB has 20,605,349 shares outstanding.
What happened to Xbrane Biopharma AB’s price movement after its last earnings report?
Xbrane Biopharma AB reported an EPS of -kr1.28 in its last earnings report, beating expectations of -kr1.49. Following the earnings report the stock price went down -13.017%.
Which hedge fund is a major shareholder of Xbrane Biopharma AB?
Currently, no hedge funds are holding shares in SE:XBRANE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Xbrane Biopharma AB
Xbrane Biopharma AB (publ), a biotechnology company, develops, manufactures, and sells biosimilars. The company is developing Xlucane, a ranibizumab biosimilar that is in Phase III clinical trials used for the treatment of wet age-related macular degeneration, diabetic macular edema, diabetic related retinopathy, and retinal vein occlusion. Its pre-clinical phase products include Xcimzane for rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis and crohn diseases; Xoncane for acute lymphocytic leukemia; Spherotide for prostate cancer, breast cancer, endometriosis, and myoma; and Xdivane for melanoma, lung, head and throat, bladder, and urinary tract cancer, as well as for renal cell carcinoma. The company has a strategic biosimilar development partnership with STADA Arzneimittel AG to evaluate development and commercialization collaborations around its Xcimzane and Xdivane preclinical biosimilars. Xbrane Biopharma AB (publ) was founded in 2008 and is headquartered in Solna, Sweden.
Technical Analysis
Ascelia Pharma AB
―
Intervacc AB
―
Guard Therapeutics International AB
―
Active Biotech AB
―
Immunicum AB
―
Options Prices
Currently, No data available
---